David Daboush News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article REHOVOT and JERUSALEM , Israel, April 6, 2021 /PRNewswire/ -- MyBiotics Pharma Ltd. http://biomx.com/, a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have entered into a research collaboration and licensing agreement for the identification of microbiome-based therapeutics that will enhance the response to and reduce adverse effects of anti-PD-1 and anti-PD-L1 in melanoma patients. The collaboration will combine Hadassah's knowhow and experti...

Shoshanna Solomon is The Times of Israel's Startups and Business reporter A 3D illustrative image of rod-shaped bacteria and cocci in the human microbiome (Dr_Microbe; iStock by Getty Images) MyBiotics Pharma Ltd. said Tuesday it will work with Hadasit Medical Research Services and Development Ltd., the technology transfer arm of Hadassah Medical Center, to identify microbiome-based therapies to improve the impact of cancer immunotherapies in melanoma patients. MyBiotics has developed technologies to culture, ferment and deliver highly stable and diverse bacterial communities that can target ...

Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV). The agreement looks to expand on each firms’ expertise in reproductive medicine and women’s health, by creating standardised, stable live microbiota-based formulations addressing the vaginal infection. Common among women of reproductive age, the condition is linked to an increased risk of miscarriage, as well as problems during pregnancy and fertility issues. “Today’s agreeme...

Antibiotic-free remedy aims to conquer bacterial vaginosis Ferring, Rebiotix and MyBiotics collaborate to develop live microbiome-based biotherapeutics in reproductive medicine and maternal health. Illustrative photo by Imani Bahati on Unsplash A live biotherapeutic remedy based on a woman’s female microbiome is under development to treat bacterial vaginosis. This common infection among women of reproductive age is linked to increased risk of miscarriage and complications to pregnancy and fertility. The treatment is being developed in a partnership among Ferring Pharmaceuticals of Switzerla...

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility.1,2,3 The collaboration is an important step forward in harnessing the power of the human microbiome...